

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 October 2001 (04.10.2001)

PCT

(10) International Publication Number
WO 01/72684 A1

- (51) International Patent Classification⁷: C07C 211/24, 209/68
- (21) International Application Number: PCT/IN01/00049
- (22) International Filing Date: 27 March 2001 (27.03.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
979/BOM/99 29 March 2000 (29.03.2000) IN
- (71) Applicant (for all designated States except US): SUN PHARMACEUTICAL INDUSTRIES LTD. [IN/IN]; Acme Plaza, Andheri-Kurla Road, Andheri (E), Mumbai 400 059, Maharashtra (IN).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): CHITTURI, Trinadha, Rao [IN/IN]; Sun Pharma Advanced Research Centre, Akota Road, Akota, Baroda 390 020, Gujarat (IN). THENNATI, Rajamannar [IN/IN]; Sun Pharma Advanced Research Centre, Akota Road, Akota, Baroda 390 020, Gujarat (IN).
- (74) Agents: MAJUMDAR, S. et al.; S. Majumdar & Co., 5, Harish Mukherjee Road, Calcutta 700 025 (IN).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR THE PREPARATION OF POLYMORPH OF 4-(ARYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALE-NAMINE DERIVATIVE

(57) Abstract: A process for the preparation of a polymorph of 4-(aryl)-1,2,3,4-tetrahydro-1-naphthalenamine derivative, a hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine, comprising adding hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine to an alkanol - water solvent system, heating to dissolve and cooling the solution to allow crystallization to occur so as to obtain Form V.


WO 01/72684 A1

FPN3/43

PROCESS FOR THE PREPARATION OF POLYMORPH OF 4-(ARYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE DERIVATIVE

FIELD OF THE INVENTION

This invention relates to a process for the preparation of a polymorph of hydrochloride salt of (1S, 4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine, a compound of formula 1. The hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is useful in the treatments of depression, obsessive-compulsive disorder and panic disorder.



Formula 1

15 BACKGROUND OF THE INVENTION

(1S, 4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine and a process for making it is disclosed in United States Patent No. 4,536,518 (Welch, Jr. et al, issued Aug 20, 1985 – Indian Reference not available) assigned to Pfizer, Inc.

20 The hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is known to exist in several different crystalline forms. United States Patent No. 5,248,699 (Sysko et al, issued Sep 28, 1993 – Indian Reference not available) assigned to Pfizer Inc. discloses five polymorphic forms, namely Form I, Form II, Form III, Form IV and Form V. The crystal densities of the crystalline forms were 1.354, 25 1.314, 1.313, 1.349, and 1.308 for Form I, Form II, Form III, Form IV and Form V; respectively. The patent reports Form I which has the highest crystal density to be the most thermodynamically stable form. It is suggested that this makes Form I the most suitable crystal form for formulation, however, it has been reported by others - United States Patent No. 5,734,083 (Indian Reference not available) that Form I dissolves too 30 slowly to provide the desired bioavailability from a pharmaceutical formulation.

The processes for preparation of polymorphic forms I to V of the hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine are disclosed in United States Patent No. 5,248,699 (Indian Reference not available). Form I is prepared by crystallization over a period of about 3 hours in an acidic solution using
5 solvent such as isopropanol, hexane, ethyl acetate, acetone, methyl isobutyl ketone and glacial acetic acid at crystallization temperature from about 20°C to about 100°C. Forms II and IV may be formed by rapid crystallization from an organic solvent. Form III is produced by heating Forms I, II or IV to above about 180°C. It is reported that Form V may be prepared by sublimation of the hydrochloride salt of (1S, 4S) N-methyl-4-(3,4-
10 dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine at a reduced pressure at a temperature from about 180°C to about 190°C.

United States Patent No. 5,734,083 (Wilson et al, issued Mar 31, 1998 – Indian Reference not available) assigned to Torcan Chemical Ltd., (Indian Reference not
15 available) discloses a novel polymorph T₁, which is reported to have an acceptable stability and a much-improved bioavailability as compared to Form I. This polymorph T₁ is obtained by treating a slurry or solution of free base, (1S, 4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine in an organic solvent such as toluene with a polar solvent such as ethyl acetate, diethyl ether or mixtures thereof, so as
20 to form a solution of the free base in the polar solvent; and acidifying the mixture by the addition of a solution of hydrogen chloride (1 – 10% w/w) in an organic solvent such as ethyl acetate.

Polymorph Form V of (1S, 4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-
25 naphthalenamine hydrochloride is reportedly prepared by process of sublimation under reduced pressure. The objective of the present invention is to prepare polymorphic Form V of the hydrochloride salt of (1S, 4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine by a simple method.

30 Although Form I is the most stable crystalline form, we have found that Form V prepared by the process of the present invention is stable under a variety of conditions that one may encounter during processing and storage of pharmaceutical formulations. For

example, it was stable for 3 months at 40°C and 75% relative humidity or when subjected to grinding in a pestle and mortar or when heated upto 140°C for 3 hours.

OBJECTIVE OF THE INVENTION

- 5 The objective of the present invention is to develop a simple method to prepare Form V of the hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine.

We have found that Form V of the hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine may be conveniently prepared by adding the hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine to an alkanol-water solvent system; heating to dissolve; and cooling the solution to allow crystallization to occur so as to obtain Form V.

SUMMARY OF THE PRESENT INVENTION

- Thus the present invention relates to a process for the preparation of a polymorph of hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine, comprising adding the hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine to an alkanol-water solvent system, heating to dissolve and cooling the solution to allow crystallization to occur.

BRIEF DESCRIPTION OF THE DRAWING:

- Figure 1 is a characteristic Infrared spectrum (KBr) of Form V of hydrochloride salt of (1S,4S)-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine prepared by the procedure described in Example 1.

DESCRIPTION OF THE INVENTION:

- The present invention relates to a process for the preparation of a polymorph of hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine, comprising adding the hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine to an alkanol - water solvent system, heating to dissolve and cooling the solution to allow crystallization to occur so as to obtain Form V.

The volume of alkanol-water solvent system that may be used may range from about 6 to 15 parts per unit weight of the hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine, preferably 8 to 10 parts per unit weight of the hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine and the most preferred being 9 parts per unit weight of the hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine. The hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine may be suspended in alkanol-water solvent system or hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine may be added to alkanol-water solvent system and heated for its dissolution. Hence, the sequence of addition is inconsequential.

According to an embodiment of the process of the present invention the alkanol-water system may have a relative proportion ranging from 5:1 to 20:1 parts by volume, preferably 5:1 to 10:1 parts by volume and most preferably 8:1 parts by volume.

According to a preferred embodiment of the process of the present invention the alkanol is selected from C₁ to C₄ alkanol, more preferably methanol or 2-propanol.

According to the process of the present invention the most preferred alkanol is 2-propanol.

According to one embodiment of the process of the present invention a polyol, selected from glycerol, mannitol, sorbitol, inositol, xylitol, 1,3-butanediol, 1,2-propanediol and the like, is added to the alkanol-water solvent system. Generally 0 to 25 mole% of the polyol with respect to hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine, is added to the solvent system and preferably 10 mole%.

The polyol may be incorporated into the alkanol-water system before, during or after the stage of dissolution of hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine with heating. The polyol may be incorporated

preferably as in Example 1 i.e. dissolved in water and then alkanol added because the dissolution of certain polyol like mannitol is slow in alkanol-water mixture. However, the sequence of addition of the polyol should not affect the formation of form V, since the crystallization is occurring from a clear solution.

5

According to the process of the present invention the dissolution of hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine may be achieved by heating the solution. Generally the solution is heated to a temperature greater than about 40°C.

10

According to the preferred embodiment of the process of the present invention the dissolution of hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine may be achieved by heating the solution to reflux temperature.

15

According to the process of the present invention the solution may be cooled to below room temperature to allow crystallization to occur.

According to the preferred embodiment of the process of the present invention the
20 solution is cooled to 20–30°C to allow crystallization to occur.

According to yet another embodiment of the process of the present invention the solution is allowed to cool for a period of 2 to 8 hours to allow crystallization to occur.

25 According to the most preferred embodiment of the process of the present invention the solution is cooled to 20–30°C over a period of 2 to 8 hours to allow crystallization to occur.

According to the process of the present invention the product may be dried using any
30 conventional drying techniques which may be suitable for the product such as fluidized bed drying, tray drying, rotary drying, drying at reduced pressures, freeze drying or spray drying. Driers that have agitational means are preferred.

EXAMPLES

The invention is further illustrated but not restricted by the description in the following examples.

5 Example 1

40.0 g (0.2189 moles) of mannitol is dissolved in 1.05 L water and to this solution is added 6.0 L of 2-propanol, followed by hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine, 750.0 g (2.189 moles). The suspension is heated to reflux temperature until a clear solution results (1-1.5 hr). The solution is then gradually cooled to 25-30°C (6 hr) to crystallize and the mixture further stirred at 25-30°C for 3 hr. The product is filtered, washed with 400.0 ml 2-propanol and dried in air oven at 60°C to constant weight.

The Infrared spectrum (KBr) showed that product was Form V of the hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine. The infrared spectrum is given in Figure 1.

No change in Infrared spectrum (KBr) and X-ray diffractogram was observed after 3 months at 40°C and 75% relative humidity or when subjected to grinding in a pestle and mortar or when heated upto 140°C for 3 hours.

20 Example 2

5 g (14.59) of hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine, is suspended in 40 ml of 2-propanol, 5 ml water is added and the mixture refluxed until a clear solution resulted (10-15 min). The resulting solution is gradually cooled to 25-30°C, and then further stirred at this temperature for 3 hr. The product is filtered and dried in air oven at 60°C to constant weight.

This experiment was repeated using 2-propanol quantities ranging from 5 to 20 parts volume with respect to water. In all the cases same polymorph (form V) was obtained.

30 The process was repeated with 10 kg input of hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine. The Infrared spectrum (KBr) and X-ray diffractogram showed that Form V of hydrochloride salt of (1S,4S) N-methyl-

4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine was obtained in a yield of 81.7%.

Example 3

- 5 Method of example 1 was followed except that sorbitol was used in the place of mannitol. Form V of the hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine was obtained.

Example 4

- 10 The crystal form of hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine prepared as per Examples 1 and 2 was subjected to powder x-ray diffraction analysis using copper x-ray source. Table 1 gives the x-ray diffraction data and Table 2 gives the crystal parameters for the hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine prepared
15 as per Examples 1 and 2

Table 1 : X-ray Diffraction Data

Example 1			Example 2		
Degrees 2 θ	D	Intensity %	Degrees 2 θ	d	Intensity %
10.5	8.4	28.0	10.6	8.3	29.7
11.1	8.0	100.0	11.1	7.9	100.0
14.3	6.2	36.5	14.4	6.2	33.1
16.5	5.4	20.4	16.6	5.3	26.3
17.3	5.1	28.3	17.4	5.1	29.4
19.8	4.5	33.6	19.9	4.5	42.4
25.5	3.5	77.2	25.5	3.5	92.9
26.1	3.4	28.8	26.1	3.4	36.4
29.2	3.1	29.6	29.2	3.1	39.8

Table 2 : Crystal Parameters

	Units	Example 1	Example 2
		Monoclinic	Monoclinic
a	Angstrom	17.423	17.314
b	Angstrom	9.138	9.172
c	Angstrom	5.545	5.548
α	in degrees	90.00	90.00
β	in degrees	104.07	104.23
γ	in degrees	90.00	90.00
V	Angstrom ³	856.75	854.15

5

10

15


20

25

CLAIMS

1. A process for the preparation of a polymorph of hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine, comprising adding the hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-
5 1,2,3,4-tetrahydro-1-naphthalenamine to an alkanol – water solvent system, heating to dissolve and cooling the solution to allow crystallization to occur so as to obtain Form V.
2. A process as claimed in claim 1 wherein the alkanol is selected from C₁ to C₄
10 alkanol.
3. A process as claimed in claim 2 wherein the alkanol is 2-propanol.
4. A process as claimed in claim 1 wherein a polyol, selected from glycerol,
15 mannitol, sorbitol, inositol, xylitol, 1,3-butanediol and 1,2-propanediol, is added to the alkanol-water solvent system.
5. A process as claimed in claim 1 wherein the solution is cooled to 20-30°C.
- 20 6. A process as claimed in claim 1 wherein the crystallization occurs over a period of about 2 to 8 hours.
7. A process as claimed in claim 1 wherein the solution is cooled to 20-30°C over a period of about 2 to 8 hours to allow crystallization to occur.
- 25 8. A process as claimed in claim 1 wherein the hydrochloride salt of (1S,4S) N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine exhibits an x-ray powder diffraction pattern having characteristic peaks expressed in degrees 2θ at approximately 10.5, 11.1, 14.3, 16.5, 17.3, 19.8, 25.5, 26.1, 29.2.
- 30 9. A process as claimed in claims 1 to 8 substantially as herein described and illustrated by examples 1 to 4.

1/1



INTERNATIONAL SEARCH REPORT

International application No.
PCT/IN 01/00049

CLASSIFICATION OF SUBJECT MATTER

IPC⁷: C07C 211/24; C07C 209/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁷: C07C 211/24; C07C 209/68

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN:CAS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5248699 A (R.J. SYSKO et al.) 28 September 1993 (28.09.93) <i>column 10, line 56-58; claims 1-7.</i>	1-9
A	US 5734083 A (A.J. WILSON et al.) 31 March 1998 (31.03.98) <i>the whole document.</i>	1-9
A	US 5082970 A (T.F. BRAISH) 21 January 1992 (21.01.92) <i>claims.</i>	1-9
A	WO 92/15552 A1 (PFIZER INC.) 17 September 1992 (17.09.92) <i>the whole document.</i>	1-9
P,X	WO 00/32551 A1 (TEVA PHARMACEUTICAL) 8 June 2000 (08.06.00) <i>examples 3-13; claims 1-6, 28-31.</i>	1-9

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

- „A“ document defining the general state of the art which is not considered to be of particular relevance
- „E“ earlier application or patent but published on or after the international filing date
- „L“ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- „O“ document referring to an oral disclosure, use, exhibition or other means
- „P“ document published prior to the international filing date but later than the priority date claimed

- „T“ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- „X“ document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- „Y“ document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- „&“ document member of the same patent family

Date of the actual completion of the international search
3 July 2001 (03.07.2001)

Date of mailing of the international search report
18 July 2001 (18.07.2001)

Name and mailing address of the ISA/AT
Austrian Patent Office
Kohlmarkt 8-10; A-1014 Vienna
Facsimile No. 1/53424/535

Authorized officer
HOFBAUER
Telephone No. 1/53424/225

Information on patent family members

Inter. Appl. No.

PCT/IN 01/00049

Patent document cited in search report			Publication date	Patent family member(s)			Publication date
US	A	5082970	21-01-1992	AT	E	133655	15-02-1996
				AU	A1	16445/92	06-10-1992
				AU	B2	647620	24-03-1994
				BR	A	9205727	27-12-1994
				CA	AA	2105393	07-09-1992
				CA	C	2105393	02-01-1996
				CN	A	1064480	16-09-1992
				CN	B	1040641	11-11-1998
				CZ	B6	285170	16-06-1999
				DE	C0	69208080	14-03-1996
				DE	T2	69208080	30-05-1996
				DK	T3	575507	09-04-1996
				EG	A	20002	27-02-1997
				EP	A1	575507	29-12-1993
				EP	B1	575507	31-01-1996
				ES	T3	2083741	16-04-1996
				FI	A	933860	03-09-1993
				FI	A0	933860	03-09-1993
				GR	T3	3019040	31-05-1996
				HU	A0	9302515	28-12-1993
				HU	A2	67707	28-04-1995
				HU	B	217064	29-11-1999
				IE	A1	920698	09-09-1992
				IE	B	70061	16-10-1996
				IL	A0	101082	15-11-1992
				IL	A1	101082	31-01-1996
				JP	T2	6505492	23-06-1994
				JP	B2	2736167	02-04-1998
				KR	B1	169750	20-03-1999
				MX	A1	9200953	23-11-1992
				NO	A	933141	03-09-1993
				NO	A0	933141	03-09-1993
				NO	B	179609	05-08-1996
				NO	C	179609	13-11-1996
				NZ	A	241844	27-07-1993
				PL	B1	166756	30-06-1995
				PT	A	100189	31-05-1993
				PT	B	100189	30-06-1993
				RU	C1	2073493	08-05-1997
				WO	A1	9215552	17-09-1992
				ZA	A	9201641	06-09-1993
				CZ	A3	9203956	15-12-1993
US	A	5248699	28-09-1993	JP	A2	6199743	19-07-1994
US	A	5734083	31-03-1998	none			
WO	A	0032551		none			
WO	A1	9215552	17-09-1992	AT	E	133655	15-02-1996
				AU	A1	16445/92	06-10-1992
				AU	B2	647620	24-03-1994
				BR	A	9205727	27-12-1994
				CA	AA	2105393	07-09-1992
				CA	C	2105393	02-01-1996
				CN	A	1064480	16-09-1992
				CN	B	1040641	11-11-1998
				CZ	B6	285170	16-06-1999
				DE	C0	69208080	14-03-1996
				DE	T2	69208080	30-05-1996
				DK	T3	575507	09-04-1996
				EG	A	20002	27-02-1997
				EP	A1	575507	29-12-1993
				EP	B1	575507	31-01-1996
				ES	T3	2083741	16-04-1996
				FI	A	933860	03-09-1993
				FI	A0	933860	03-09-1993
				GR	T3	3019040	31-05-1996
				HU	A0	9302515	28-12-1993
				HU	A2	67707	28-04-1995
				HU	B	217064	29-11-1999
				IE	A1	920698	09-09-1992
				IE	B	70061	16-10-1996
				IL	A0	101082	15-11-1992
				IL	A1	101082	31-01-1996
				JP	T2	6505492	23-06-1994
				JP	B2	2736167	02-04-1998
				KR	B1	169750	20-03-1999
				MX	A1	9200953	23-11-1992

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/IN 01/00049

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		NO A 933141	03-09-1993
		NO A0 933141	03-09-1993
		NO B 179609	05-08-1996
		NO C 179609	13-11-1996
		NZ A 241844	27-07-1993
		PL B1 166756	30-06-1995
		PT A 100189	31-05-1993
		PT B 100189	30-06-1999
		RU C1 2079483	20-05-1997
		US A 5082970	21-01-1992
		ZA A 9201641	06-09-1993
		CZ A3 9203956	15-12-1993